Seelos Therapeutics (SEEL) Revenue & Revenue Breakdown
Seelos Therapeutics Revenue Highlights
Latest Revenue (Y)
$2.20M
Latest Revenue (Q)
$579.00K
Seelos Therapeutics Revenue by Period
Seelos Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $2.20M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2019-12-31 | $375.00K | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | -100.00% |
| 2016-12-31 | $5.76M | 19.09% |
| 2015-12-31 | $4.84M | -47.74% |
| 2014-12-31 | $9.26M | 268.74% |
| 2013-12-31 | $2.51M | -70.16% |
| 2012-12-31 | $8.42M | 105.21% |
| 2011-12-31 | $4.10M | -17.53% |
| 2010-12-31 | $4.97M | 67.22% |
| 2009-12-31 | $2.97M | -50.08% |
| 2008-12-31 | $5.96M | 368.96% |
| 2007-12-31 | $1.27M | -31.95% |
| 2006-12-31 | $1.87M | -22.18% |
| 2005-12-31 | $2.40M | 567.60% |
| 2004-12-31 | $359.37K | 224.51% |
| 2003-12-31 | $110.74K | -25.19% |
| 2002-12-31 | $148.03K | 117.40% |
| 2001-12-31 | $68.09K | 6808800.00% |
| 2000-12-31 | $1.00 | -100.00% |
| 1999-12-31 | $1.50M | -73.73% |
| 1998-12-31 | $5.71M | 10063.03% |
| 1997-12-31 | $56.17K | - |
Seelos Therapeutics generated $2.20M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Seelos Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $579.00K | -11.33% |
| 2023-12-31 | $653.00K | 60.84% |
| 2023-09-30 | $406.00K | 20.83% |
| 2023-06-30 | $336.00K | -58.42% |
| 2023-03-31 | $808.00K | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | -100.00% |
| 2020-12-31 | $14.30M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $375.00K | - |
| 2019-09-30 | $375.00K | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | -100.00% |
| 2016-12-31 | $356.00K | -91.75% |
| 2016-09-30 | $4.32M | 830.39% |
| 2016-06-30 | $464.00K | -25.88% |
| 2016-03-31 | $626.00K | -76.19% |
| 2015-12-31 | $2.63M | 106.52% |
| 2015-09-30 | $1.27M | 175.54% |
| 2015-06-30 | $462.00K | -2.74% |
| 2015-03-31 | $475.00K | -75.09% |
| 2014-12-31 | $1.91M | 0.47% |
| 2014-09-30 | $1.90M | -65.20% |
| 2014-06-30 | $5.45M | 100.00% |
| 2014-03-31 | - | -100.00% |
| 2013-12-31 | $362.00K | 1192.86% |
| 2013-09-30 | $28.00K | -97.65% |
| 2013-06-30 | $1.19M | 16.98% |
| 2013-03-31 | $1.02M | -56.88% |
| 2012-12-31 | $2.36M | -54.13% |
| 2012-09-30 | $5.15M | 4206.26% |
| 2012-06-30 | $119.63K | -84.69% |
| 2012-03-31 | $781.48K | 554.02% |
| 2011-12-31 | $119.49K | -85.05% |
| 2011-09-30 | $799.42K | -49.88% |
| 2011-06-30 | $1.60M | 0.51% |
| 2011-03-31 | $1.59M | 84.00% |
| 2010-12-31 | $862.52K | -27.73% |
| 2010-09-30 | $1.19M | -18.86% |
| 2010-06-30 | $1.47M | 1.74% |
| 2010-03-31 | $1.45M | 390.36% |
| 2009-12-31 | $294.83K | 169.03% |
| 2009-09-30 | $109.59K | 6.80% |
| 2009-06-30 | $102.61K | -95.84% |
| 2009-03-31 | $2.47M | -29.53% |
| 2008-12-31 | $3.50M | 1044.05% |
| 2008-09-30 | $305.94K | -74.50% |
| 2008-06-30 | $1.20M | 26.04% |
| 2008-03-31 | $951.79K | 135.82% |
| 2007-12-31 | $403.60K | - |
Seelos Therapeutics generated $579.00K in revenue during Q1 2024, up -11.33% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Seelos Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CAPR | Capricor Therapeutics | $25.18M | $3.97M |
| ITOS | iTeos Therapeutics | $12.60M | - |
| PULM | Pulmatrix | $7.30M | $1.55M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| HSTO | Histogen | $3.77M | $5.00K |
| SEEL | Seelos Therapeutics | $2.20M | $579.00K |
| OPT | Opthea | $108.41K | $61.27K |
| SLNO | Soleno Therapeutics | - | - |
| GHRS | GH Research | - | $80.00K |
| ATAI | Atai Life Sciences | - | - |
| AKTX | Akari Therapeutics | - | - |
| ENTX | Entera Bio | - | $57.00K |
| ELYM | Eliem Therapeutics | - | - |
| TPST | Tempest Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| MNMD | Mind Medicine (MindMed) | - | - |
| DFFN | CervoMed | - | - |
SEEL Revenue FAQ
What is Seelos Therapeutics’s yearly revenue?
Seelos Therapeutics's yearly revenue for 2023 was $2.2M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. SEEL's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Seelos Therapeutics’s quarterly revenue?
Seelos Therapeutics's quarterly revenue for Q1 2024 was $579K, a -11.33% decrease from the previous quarter (Q4 2023), and a -28.34% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $653K, a 60.84% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). SEEL's quarterly revenue for Q3 2023 was $406K, a 20.83% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Seelos Therapeutics’s revenue growth rate?
Seelos Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 487.47%.